Women who received cabergoline, a pill used to stop breast milk production, were about 70% less likely to develop breast cancer in the following years than women who did not, according to a study of health records from more than 150,000 women in Spain and Norway. The research was published in Cancer Discovery, a journal of the American Association for Cancer Research, on Oct. 15.
The finding is an association, not proof that the drug prevents cancer. The human data come from health records, and no woman was randomly assigned to take the drug. The researchers say a clinical trial is needed to find out whether the benefit is real.
